PRC2 alterations in NF1-associated malignant peripheral nerve sheath tumors: Schwann cells with no complex;Altérations du PRC2 au sein des tumeurs malignes associées à la neurofibromatose de type 1: des cellules de Schwann sans aucun complexe !

Medecine/Sciences

Volumn 30, Issue 8-9, 2014, Pages 733-735

  Luscan, Armelle ^a,b   Vidaud, Dominique ^a,b   Ortonne, Nicolas ^c   Wolkenstein, Pierre ^d   Vidaud, Michel ^a,b   Pasmant, Éric ^a,b  

^a Service de Biochimie et de Génétique Moléculaire Hôpital Cochin AP HP ^*  (France)

^b INSERM   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEURILEMOMA; PATHOLOGY; PHYSIOLOGY; SCHWANN CELL; TUMOR SUPPRESSOR GENE;

CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEUROFIBROMATOSIS 1; HISTONE ACETYLTRANSFERASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MUTATION; NEURILEMMOMA; POLYCOMB REPRESSIVE COMPLEX 2; SCHWANN CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906842299     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20143008006     Document Type: Article

References (11)

1. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
2. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12: 283-285.
3. Sabbagh A, Pasmant E, Imbard A, et al. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat 2013; 34: 1510-1518.
4. Pasmant E, Sabbagh A, Spurlock G, et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 2010; 31: E1506-E1518.
5. Sabbagh A, Pasmant E, Laurendeau I, et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 2009; 18: 2768-2778.
6. Pasmant E, Sabbagh A, Masliah-Planchon J, et al. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst 2011; 103: 1713-1722.
7. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
8. Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298-301.
9. De Raedt T, Beert E, Pasmant E, et al. PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to epigenetic-based therapies. Nature 2014. (sous presse).
10. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014; 13: 337-356.
11. Pasmant E, Laurendeau I, Sabbagh A, et al. ANRIL ou l'étrange histoire d'un grand ARN non codant. Med Sci (Paris) 2010; 26: 564-566.